Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topical corticosteroid Rx-to-OTC switch

Executive Summary

Safety data for over-the-counter switches of topical corticosteroid products will be discussed at a joint meeting of FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees on March 24. The committees will focus particularly on the evaluation of the potential for hypothalamic, pituitary, adrenal (HPA) and growth suppression and other systemic and local adverse events with topical steroids. The meeting will take place at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...

You may also be interested in...



India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

QUOTED. 5 March 2021. Dedi Gilad.

Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.

Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?

Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel